 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
AngioDynamics, Inc. (ANGO) designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally.
The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors.
It also offers BioSentry tract sealant systems; IsoLoc Endorectal Balloon's; alatus vaginal balloon packing systems; and OARtrac system, which offers real-time dose data physically delivered during various cancer treatments.
In addition, the company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases.
Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships.
The company reports its quarterly results on the 7th. We expect a strong report. On October 3rd, it reported 1st Quarter August 2019 earnings of $0.08 per share on revenue of $66.0 million. The consensus earnings estimate was $0.04 per share on revenue of $67.6 million. Revenue fell 22.6% compared to the same quarter a year ago.
The company said it now expects fiscal 2020 earnings of $0.10 to $0.15 per share and continues to expect revenue of $280.0 million to $286.0 million.
Entry Point: $16.45
Stop loss: $15.50
Trading Range: $13.72 to $25.48
Target Price: $19.00
ANGO closed at $15
